2J. I. Davies,M. Band,A. Morris,A. D. Struthers. Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes[J] 2004,Diabetologia(10):1687～1694
二级参考文献5
1Hollenberg NK.Aldosterone in the development and progression of renal injury.Kindney Int,2004,66:1-9.
2Feria I,Pichardo I,Juarez P,et al.Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.Kidney Int,2003,63:43-52.
3Zhu S,Liu J,Chen L,et al.Chemopreventive effect of five drugs on renal interstitial fibrosis induced by an aristolochic acid-containing Chinese herb in rats.Am J Nephrol,2005,25:23-29.
4Fujisawa G,Okada K,Muto S,et al.Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.Kidney Int,2004,66:1493-502.
5Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention,Detection,Evaluation,and Treatment of High Blood Pressure:the JNC 7 report[J].JAMA,2003,289(19):2560-72.
6Locatelli F,Del Vecchio L,Pozzoni P,et al.Is it the agent or the blood pressure level that matters for renal and vascular protection in chronic nephropathies[J].Kidney Int Suppl,2005,93:15-1.
7MyrupB,Rossing P,Jensen T,et al.Procoagulant activity and intimal dysfunction in IDDM[J].Diabetologia,1995,38:73-78.
